AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11240880 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 22.5 mg.kg-1
Number of subjects: 21
Study 9240263 — intervention group
Group type: COMPARATOR
Intervention: Intact germinal vesicle with cumulus (Group 1)
Number of subjects: 80
Study 9240263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact germinal vesicle with sperm cells (Group 2)
Number of subjects: 80
Study 9240263 — intervention group
Group type: COMPARATOR
Intervention: Stripped germinal vesicle (Group 3)
Number of subjects: 80
Study 9240263 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripped germinal vesicle with sperm cells (Group 4)
Number of subjects: 80
Study 8494126 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg
Number of subjects: 29
Study 8494126 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 29
Study 8494126 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg
Number of subjects: 29
Study 3682574 — intervention group
Group type: EXPERIMENTAL
Intervention: reserpin (0.5‐0.75 mg/day)
Number of subjects: 294
Study 3682574 — intervention group
Group type: EXPERIMENTAL
Intervention: dopegyt (750‐1500 mg/day)
Number of subjects: 294
Study 3682574 — intervention group
Group type: EXPERIMENTAL
Intervention: clophelin (0.3‐0.6 mg/day)
Number of subjects: 294
Study 3682574 — intervention group
Group type: EXPERIMENTAL
Intervention: anaprilin (80‐160 mg/day)
Number of subjects: 294
Study 3682574 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (25‐100 mg/day)
Number of subjects: 294
Study 3682574 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 294
Study 29900819 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 90
Study 29900819 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 90
Study 28687830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab added to weekly concurrent cisplatin (50 mg/m2), paclitaxel (25 mg/m2), and daily radiation of 50.4 Gy/1.8 Gy fractions.
Number of subjects: 328
Study 28687830 — intervention group
Group type: COMPARATOR
Intervention: Weekly concurrent cisplatin (50 mg/m2), paclitaxel (25 mg/m2), and daily radiation of 50.4 Gy/1.8 Gy fractions without cetuximab.
Number of subjects: 328
Study 28687830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab added to concurrent chemoradiation.
Number of subjects: 328
Study 28687830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cetuximab).
Number of subjects: 328
Study 25385096 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine alone (30 mg base)
Number of subjects: 17
Study 25385096 — intervention group
Group type: COMPARATOR
Intervention: Pyronaridine-artesunate alone (540-180 mg)
Number of subjects: 17
Study 25385096 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate plus primaquine
Number of subjects: 17
Study 23266402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized Dornase alfa administered twice daily until extubation, death, or transfer
Number of subjects: 30
Study 23266402 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily until extubation, death, or transfer
Number of subjects: 30
Study 21252053 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated reminders with printed summaries for overdue CD4 tests
Number of subjects: 717
Study 21252053 — intervention group
Group type: COMPARATOR
Intervention: Control clinic without reminders
Number of subjects: 717
Study 21252053 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated reminders (regardless of printed summaries)
Number of subjects: 717
Study 21252053 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed summaries with reminders
Number of subjects: 717
Study 18379765 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 20
Study 18379765 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 17000366 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 300
Study 17000366 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer greater than 4.1 mmol/L
Number of subjects: 300
Study 12921250 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network
Number of subjects: 55
Study 12921250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach
Number of subjects: 55
Study 12921250 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward stepwise regression LSM
Number of subjects: 55
Study 10937110 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaved eyebrow
Number of subjects: 5
Study 10937110 — intervention group
Group type: COMPARATOR
Intervention: Unshaven eyebrow (control)
Number of subjects: 5
Study 10937110 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaved eyebrow (specific case)
Number of subjects: 5
Study 8682466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined locoregional immuno-chemotherapy (Group B)
Number of subjects: 48
Study 8682466 — intervention group
Group type: COMPARATOR
Intervention: Locoregional chemotherapy (Group A)
Number of subjects: 48
Study 1868748 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine gel 1 percent applied twice daily for four weeks
Number of subjects: 316
Study 1868748 — intervention group
Group type: COMPARATOR
Intervention: Gel vehicle applied twice daily for four weeks
Number of subjects: 316
Study 1868748 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine gel 1 percent
Number of subjects: 316
Study 6922161 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral orientation to infant's behavior (Group I)
Number of subjects: 40
Study 6922161 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral orientation to infant's behavior (Group II)
Number of subjects: 40
Study 6922161 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpretested mothers (Group III)
Number of subjects: 40
Study 6922161 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group IV)
Number of subjects: 40
Study 30985379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg/kg
Number of subjects: 64
Study 30985379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 64
Study 30985379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg/kg
Number of subjects: 64
Study 30985379 — intervention group
Group type: COMPARATOR
Intervention: Control (0 µg/kg)
Number of subjects: 64
Study 29724499 — intervention group
Group type: COMPARATOR
Intervention: Placebo TID
Number of subjects: 135
Study 29724499 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 250 mg TID
Number of subjects: 135
Study 29724499 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 500 mg TID
Number of subjects: 135
Study 26950696 — intervention group
Group type: EXPERIMENTAL
Intervention: Water provision (bottle of drinking water that could be refilled throughout the day)
Number of subjects: 292
Study 26950696 — intervention group
Group type: COMPARATOR
Intervention: Control (access to drinking water normally available at the school)
Number of subjects: 292
Study 26950696 — intervention group
Group type: EXPERIMENTAL
Intervention: Water provision and hydration
Number of subjects: 292
Study 24281785 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma (NTG)
Number of subjects: 197
Study 24281785 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 197
Study 24281785 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 197
Study 22189260 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to starchy table foods (yes)
Number of subjects: 61
Study 22189260 — intervention group
Group type: COMPARATOR
Intervention: Exposure to fruit table food (no)
Number of subjects: 61
Study 22189260 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating starchy table foods at 6 months
Number of subjects: 61
Study 21035187 — intervention group
Group type: EXPERIMENTAL
Intervention: KEEP parenting program (intervention)
Number of subjects: 359
Study 21035187 — intervention group
Group type: EXPERIMENTAL
Intervention: PDR ratings (intervention)
Number of subjects: 359
Study 21035187 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported stress (intervention)
Number of subjects: 359
Study 17333382 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Relationships intervention (HR-A)
Number of subjects: 0
Study 17333382 — intervention group
Group type: COMPARATOR
Intervention: Healthy Relationships intervention (HR-O)
Number of subjects: 0
Study 11139861 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity gel pads
Number of subjects: 120
Study 11139861 — intervention group
Group type: COMPARATOR
Intervention: Ice packs and Epifoam
Number of subjects: 120
Study 9132351 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Redon drains
Number of subjects: 100
Study 9132351 — intervention group
Group type: COMPARATOR
Intervention: No drains (Control)
Number of subjects: 100
Study 8351157 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine for 7 days pre-operatively
Number of subjects: 0
Study 8351157 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine for 3 days starting 7 days before surgery
Number of subjects: 0
Study 8351157 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine for 3 days starting 3 days pre-operatively
Number of subjects: 0
Study 8351157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3523240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampin given for five days
Number of subjects: 0
Study 3523240 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 3523240 — intervention group
Group type: EXPERIMENTAL
Intervention: Full course of rifampin
Number of subjects: 0
Study 29258789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab treatment
Number of subjects: 1192
Study 26670576 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniArc (single-incision midurethral sling)
Number of subjects: 193
Study 26670576 — intervention group
Group type: COMPARATOR
Intervention: Monarc (transobturator standard midurethral sling)
Number of subjects: 193
Study 25899986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 138
Study 25899986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine
Number of subjects: 138
Study 25899986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lomustine and bevacizumab
Number of subjects: 138
Study 25899986 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment specified)
Number of subjects: 138
Study 24088680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine-containing ART
Number of subjects: 402
Study 24088680 — intervention group
Group type: COMPARATOR
Intervention: Non-ART (control)
Number of subjects: 402
Study 20527137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone butyrate 0.1% in lipocream (HCB 0.1% LCr)
Number of subjects: 264
Study 20527137 — intervention group
Group type: COMPARATOR
Intervention: Lipocream alone (LCr)
Number of subjects: 264
Study 17586038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) materials
Number of subjects: 156
Study 17586038 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA materials
Number of subjects: 156
Study 16617220 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention based on cognitive behavioral therapy
Number of subjects: 2481
Study 16617220 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 2481
Study 12716076 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Ca‐A)
Number of subjects: 0
Study 12716076 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor (ACE‐I)
Number of subjects: 0
Study 12716076 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor antagonist (ARB)
Number of subjects: 0
Study 11066055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chemotherapy with trofosfamide (100 mg/m2) and etoposide (25 mg/m2), daily or for 21-day cycles interrupted by 1-week rests, with concurrent standard fractionated radiation (54 grays).
Number of subjects: 22
Study 11066055 — intervention group
Group type: COMPARATOR
Intervention: Control group from Surveillance, Epidemiology, and End Results data.
Number of subjects: 22
Study 8840284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic rEPO therapy
Number of subjects: 30
Study 8840284 — intervention group
Group type: COMPARATOR
Intervention: Not receiving rEPO therapy
Number of subjects: 30
Study 1632179 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium with or without lidocaine (groups A, B, C)
Number of subjects: 105
Study 1632179 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (groups F, G)
Number of subjects: 105
Study 1632179 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (group B)
Number of subjects: 105
Study 1632179 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine only (group F)
Number of subjects: 105
Study 1632179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine in combination with atracurium (group D)
Number of subjects: 105
Study 1632179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine in combination with succinylcholine (group G)
Number of subjects: 105
Study 1632179 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 105
Study 28976210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigna nakashimae extract (1 g thrice daily)
Number of subjects: 18
Study 28976210 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (control group)
Number of subjects: 18
Study 27233479 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led exercise and education intervention (6 sessions, 2 hours/week)
Number of subjects: 74
Study 27233479 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 74
Study 24226568 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate, 0.05% cream applied twice daily for 24 weeks (2 cycles of 6 weeks on, 6 weeks off)
Number of subjects: 41
Study 24226568 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone, 1% cream applied twice daily for 24 weeks (2 cycles of 6 weeks on, 6 weeks off)
Number of subjects: 41
Study 22830016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/d and Tretinoin 10 mg/BID for six months
Number of subjects: 27
Study 22830016 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Riluzole
Number of subjects: 27
Study 22830016 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (Pioglitazone and Tretinoin)
Number of subjects: 27
Study 22830016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 22830016 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of pNF-H at baseline
Number of subjects: 27
Study 20075313 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived discrimination
Number of subjects: 2561
Study 20075313 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination at school or work
Number of subjects: 2561
Study 20075313 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination at shops
Number of subjects: 2561
Study 20075313 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination by police
Number of subjects: 2561
Study 19128256 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatain Ibu Nonadhesive (foam dressing with ibuprofen)
Number of subjects: 122
Study 19128256 — intervention group
Group type: COMPARATOR
Intervention: Biatain Non-Adhesive (foam dressing without ibuprofen)
Number of subjects: 122
Study 16648092 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology treatments
Number of subjects: 0
Study 16648092 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14665498 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaifenesin (400 mg)
Number of subjects: 28
Study 14665498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 14665498 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (no intervention)
Number of subjects: 28
Study 11035667 — intervention group
Group type: EXPERIMENTAL
Intervention: European Commission for Steel and Coal questionnaire and spirometry with bronchodilator test
Number of subjects: 4035
Study 8767350 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine monotherapy (n = 32)
Number of subjects: 55
Study 8767350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Isradipine + metoprolol/enalapril) (n = 11)
Number of subjects: 55
Study 8767350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single administration of isradipine 5 mg for responsiveness testing)
Number of subjects: 55
Study 1623868 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolytic treatment with anistreplase
Number of subjects: 350
Study 1623868 — intervention group
Group type: COMPARATOR
Intervention: In-hospital thrombolytic treatment with anistreplase
Number of subjects: 350
Study 6435272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole nafate 2 gm administered intravenously preoperatively and 6 hours postoperatively in four doses
Number of subjects: 88
Study 6435272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole nafate 0.4% solution: 250 ml to irrigate the abdominal wound on opening, 500 ml to irrigate the peritoneal cavity, and 250 ml to irrigate the wound on closing
Number of subjects: 88
Study 6435272 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic plus topical administrations as in Nos. 1 and 2
Number of subjects: 88
Study 31568000 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant moxibustion therapy with usual care for 12 weeks (24 sessions)
Number of subjects: 46
Study 31568000 — intervention group
Group type: COMPARATOR
Intervention: Usual care (acetaminophen on demand and self-directed exercise education)
Number of subjects: 46
Study 31568000 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant moxibustion therapy
Number of subjects: 46
Study 31568000 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study 29856274 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Safety Training Program
Number of subjects: 83
Study 29856274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study 26883118 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellbeing interventions
Number of subjects: 110
Study 26883118 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement
Number of subjects: 110
Study 26883118 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care training
Number of subjects: 110
Study 26883118 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mapping activities and access to wellbeing interventions
Number of subjects: 110
Study 26883118 — intervention group
Group type: EXPERIMENTAL
Intervention: Health practitioner participation in community consultative groups
Number of subjects: 110
Study 25149070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 3657
Study 25149070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3657
Study 22146409 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta‐1a three times a week
Number of subjects: 517
Study 22146409 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta‐1a once a week
Number of subjects: 517
Study 22146409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study 19376326 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP risk model
Number of subjects: 279337
Study 18172677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with bilateral LLND and complete PANP
Number of subjects: 44
Study 18172677 — intervention group
Group type: COMPARATOR
Intervention: Control group with bilateral LLND and limited PANP
Number of subjects: 44
Study 18172677 — intervention group
Group type: COMPARATOR
Intervention: Overall and disease-free survival
Number of subjects: 44
Study 18172677 — intervention group
Group type: COMPARATOR
Intervention: Local recurrence
Number of subjects: 44
Study 17057788 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 23
Study 17057788 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 23
Study 12003177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) during structured treatment interruptions (STI) of HAART
Number of subjects: 0
Study 12003177 — intervention group
Group type: COMPARATOR
Intervention: Structured treatment interruptions (STI) of HAART
Number of subjects: 0
Study 10090546 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg q.i.d. for the first 3 days and b.i.d. for 7 days)
Number of subjects: 55
Study 10090546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 7768497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TMX) with triptorelin
Number of subjects: 85
Study 7768497 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide with triptorelin
Number of subjects: 85
Study 7768497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 2334391 — intervention group
Group type: EXPERIMENTAL
Intervention: Special dementia day care
Number of subjects: 0
Study 2334391 — intervention group
Group type: COMPARATOR
Intervention: Full-time institutional care
Number of subjects: 0
Study 420752 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying energy and protein intake
Number of subjects: 0
Study 420752 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein and energy levels
Number of subjects: 0
Study 31174993 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 80
Study 31174993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27288835 — intervention group
Group type: EXPERIMENTAL
Intervention: 24IU oxytocin
Number of subjects: 194
Study 27288835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 27288835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive taxation (taxed vs. not taxed)
Number of subjects: 194